News

UCB: Positive phase III results
Enlarge image

BusinessBelgium

UCB: Positive phase III results

18.04.2012 - UCBs Cimzia has succeeded in a phase III. That raises hope that the TNF-α inhibitor could gain additional sales in the highly competitive anti-inflammation market.

Brussels –  The TNF alpha inhibitor has met the primary endpoint in a phase III trial to treat adult onset of active axial spondoyloarthritis (AXSA). The study enrolled 325 patients with AXSA who were assigned to treatment with one of two doses of Cimzia (certolizumab pegol) or placebo over a 24-week period. The trial has shown a 20 per cent improvement in the Assessment of Spondyloarthritis International Society (ASAS20) response at week 12 compared to placebo. UCB expects to file for approval in this indication later this year. The pegylated humanised antibody fragment Cimzia (certolizumab pegol) is already approved in Europe and the US for rheumatoid arthritis and in the US for Crohn's disease, although the EU rejected UCB's application to market the drug in the latter indication in 2008. It is UCB's second-biggest product with sales of €312m last year, up more than 50 per cent compared to 2010. Axial spondyloarthritis is a collective name for a series of inflammatory rheumatic diseases of the spine, joints, ligaments and tendons, and includes a spinal condition known as ankylosing spondylitis. Expanding the labelling for Cimzia in this indication is important for UCB to make headway against the drug's rivals in the competitive anti-TNF alpha sectorlike Enbrel (Amgen, Pfizer and others), Humira (Abbott, Eisai ) and Johnson & Johnson's Remicade. The competitors fear the appearance of biosimilar rivals entering the market after the drug's patent expiry in 2014. In addition to the axial spondyloarthritis indications, UCB is also planning to submit Cimzia for psoriatic arthritis by the end of the year, and is also awaiting approval of the drug for rheumatoid arthritis in Japan, where it has been co-developed by Astellas Pharma. 

http://www.european-biotechnology-news.com/news/news/2012-02/positive-phase-iii-results-support-cimzia-label-expansion.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • KAROLINSKA (S)10.80 SEK3.85%

FLOP

  • THERAMETRICS (CH)0.06 CHF-14.29%
  • SCANCELL HOLDINGS (UK)27.10 GBP-10.41%
  • ALMIRALL (E)16.66 EUR-8.16%

TOP

  • PROTHENA PLC (IE)49.60 USD24.2%
  • DBV Technologies (F)52.00 EUR22.1%
  • VERONA PHARMA (UK)4.92 GBP15.8%

FLOP

  • SCANCELL HOLDINGS (UK)27.10 GBP-29.2%
  • OREXO (S)68.50 SEK-24.1%
  • NORDIC NANOVECTOR (N)27.00 NOK-23.3%

TOP

  • ADOCIA (F)64.00 EUR364.8%
  • 4SC (D)4.52 EUR352.0%
  • WILEX (D)3.69 EUR350.0%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • ACTIVE BIOTECH (S)8.75 SEK-69.8%
  • NEOVACS (F)1.11 EUR-67.3%

No liability assumed, Date: 30.06.2015